Tata India Pharma & Healthcare Fund Regular-Growth
The fund is rated 1 star. The investment selection within each asset type and balance between returns and downside risk provided some support. The investment selection within each industry was the main limitation and did not provide enough support for a higher rating. A higher annual fee of 2.37% was a minor drawback.
This fund has a ok track record with Asset Selection/Timing, a bad track record with Stock Selection/Timing. It is important to note, however, that this fund has a 1565.28 AUM and a 2.37 expense ratio. Considering all these factors, we have rated this fund as 1.0 star.
Our score weighs long-term performance, risk and consistency — not just past returns.
Returns
As of 8 Oct 2026
Risk ratios
As of 30 Sep 2026
Portfolio
As of 31 Aug 2026
Market-cap split
Sector allocation
Holdings (42)
| Holding | % of fund | Value | Shares |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 8.43% | ₹132.02 Cr | 6,65,178 |
| Healthcare Global Enterprises Ltd. | 6.30% | ₹98.56 Cr | 13,44,012 |
| Divi's Laboratories Ltd. | 5.65% | ₹88.49 Cr | 93,472 |
| Abbott India Ltd. | 5.44% | ₹85.11 Cr | 32,924 |
| Rainbow Children's Medicare Ltd. | 4.47% | ₹70.04 Cr | 4,95,081 |
| Apollo Hospitals Enterprise Ltd. | 4.32% | ₹67.64 Cr | 76,013 |
| Cipla Ltd. | 4.27% | ₹66.78 Cr | 4,73,861 |
| Dr. Reddy's Laboratories Ltd. | 4.21% | ₹65.84 Cr | 5,70,312 |
| Max Healthcare Institute Ltd. | 3.80% | ₹59.55 Cr | 5,71,483 |
| Fortis Healthcare Ltd. | 3.30% | ₹51.63 Cr | 5,69,351 |
Fund details
Long Term Capital Appreciation. Investment in equity/equity related instruments of the companies in the Pharma & Healthcare sector in India.
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Exit load of 0.25% if redeemed within 30 days.